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chow. Proteinuria, creatinine clearance, blood pressure, and 
renal quantitative histopathology markers were determined. 
 Results: Correction of renal function in ZDF by pioglitazone, 
occurring with a glycemia  1 250 mg/dl, was accompanied by 
normalization of the renal levels of connective tissue growth 
factor and fibronectin (fibrosis), TNF-  , interleukin-6 and 
MCP-1 (inflammation), megalin (tubular cells), the PCNA/cas-
pase-3 ratio (positive cell turnover), VEGF (abnormal angio-
genesis), and the ratio between eNOS and iNOS (endothelial 
dysfunction).  Conclusion: This supports mechanisms for the 
renoprotective effects of pioglitazone in diabetes additional 
to glycemic control.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 The thazolidinediones, a group of drugs that bind to 
the peroxisome proliferator-activated receptor-  (PPAR-
  ), are widely used for the treatment of type 2 diabetes 
and they lower blood glucose primarily by improving in-
sulin sensitivity in peripheral tissues  [1] . Since diabetic 
 Key Words 
 Diabetic nephropathy   Thiazolidinediones   Peroxisome 
proliferator-activated receptor-    Metabolic syndrome   
Fibrosis   Inflammation   ZDF fa/fa rat   Nitric oxide 
synthase   VEGF   Megalin 
 Abstract 
 Background/Aims: Pioglitazone and other thiazolidinedi-
ones are renoprotective in diabetic nephropathy at doses 
that normalize glycemia, presumably as a consequence of 
glycemic control. However, low doses of pioglitazone that 
did not normalize glycemia in rat models of type 2 diabetes 
prevented tubulointerstitial fibrosis and glomerulosclerosis 
through counteracting inflammation, oxidative stress, cell 
cycle arrest, and fibrosis. The current work tested whether 
this low-dose treatment also reduces other fibrosis and in-
flammation factors in the diabetic kidney and prevents tu-
bular cell loss, endothelial damage, and abnormal angiogen-
esis.  Methods: ZDF fa/fa rats (ZDF) were fed for 4 months 
chow with 0.001% pioglitazone, and the untreated ZDF and 
the non-diabetic lean Zucker rats (LZR) received regular 
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nephropathy (DN) is the most common cause of end-
stage kidney disease and the leading cause of death in 
diabetic patients  [2] , and hyperglycemia and metabolic 
syndrome are strongly associated with chronic kidney 
disease  [3] , the prevailing view is that the protective ef-
fects of these drugs on the diabetic kidney  [4–6] are due 
to their ability to exert glycemic control and to reduce 
blood pressure. However, this interpretation does not 
consider the pleiotropism of PPAR-  agonists, that ex-
ceeds their systemic effects and extends to direct local 
binding to tissue PPAR-  that may directly counteract 
chronic inflammation, oxidative stress, cytokine release, 
and eventually fibrosis, particularly in the cardiovascular 
and renal systems  [7, 8] . These mechanisms are of special 
relevance to DN, characterized by tubulointerstitial fi-
brosis and glomerulosclerosis  [9–11] , and would contrib-
ute to the lowering of blood pressure that would in turn 
hemodynamically stimulate the correction of the renal 
histopathology due to a combination of systemic and lo-
cal effects.
 The protective effects of thiazolidinediones on the di-
abetic kidney at doses that control glycemia have been 
shown in humans  [12–15] , and in rodent models of type 
1 diabetes, such as the streptozotocin-injected rat  [12, 16, 
17] , but in fact these models do not represent the com-
plexity of the impact of obesity and other factors of the 
metabolic syndrome and the influence of glycemic con-
trol. The more widely used rat models of type 2 diabetes 
are the obese Zucker fa/fa rat (OZR) and the Zucker dia-
betic fatty fa/fa rat (ZDF) that differ in the facts that the 
OZR is considerably more obese and hyperinsulinemic, 
and is less hyperglycemic than the ZDF  [18] . Several as-
pects of the pathophysiology of glomerulosclerosis and of 
tubulointerstitial fibrosis in relation to hyperglycemia 
have been clarified in these strains  [ e.g. 19, 20] . A clini-
cally used thazolidinedione, pioglitazone, has been re-
ported to be protective for the diabetic kidney, at doses 
that normalize glycemia either per se or through enhanc-
ing the renoprotective effects of an ATIIR-1 inhibitor in 
the OZR, and other agonists such as rosiglitazone and 
troglitazone exerted similar effects in the ZDF  [4–6, 21] .
 Despite this evidence, it was not clear on whether the 
renoprotection exerted by pioglitazone and other thoa-
zolidinediones in type 2 DN is due exclusively to normal-
izing glycemia via their insulin sensitizer effects, or an 
intrinsic independent and local mechanism would also 
contribute. Obviously, the reported beneficial effects of 
PPAR-  agonists in models of type 1 diabetes  [3, 16, 17] , 
where these drugs do not control glycemia, would sup-
port the latter view. Our recent study in the OZR, with a 
low dose of pioglitazone given for 5 months that does not 
change the hyperglycemia of 250 mg/dl seen in this strain 
 [22] , demonstrated the prevention of renal tissue damage 
and fibrosis, as evidenced by the glomerulosclerosis, tu-
bulointerstitial fibrosis, tubular atrophy and podocyte in-
jury indexes, as well as by the reduction in the markers of 
oxidative stress and inflammation. Essentially similar re-
sults were found in the ZDF, where glycemia is higher, but 
was not reduced below the 250 mg/dl level, showing that 
blood pressure, proteinuria and creatinine clearance were 
however virtually normalized  [22] . These results are in 
agreement with a study with pioglitazone at double the 
dose of our work given to Otsuka Long-Evans Tokushi-
ma fatty (OLETF) rats, which ameliorated DN without 
changing HbA 1c levels as a marker of cumulative hyper-
glycemia impact  [23] . This is also in agreement with our 
previous demonstration of the antifibrotic effects of pio-
glitazone independently of glycemic control in the corpo-
ral smooth muscle tissue of the penis in the OZR  [24] .
 Taken together, these results suggest that pioglitazone, 
and by inference other thiazolidinediones, protect the di-
abetic kidney, in addition to their conventional effects on 
glycemic control and the lowering of blood pressure, by 
local antioxidative and anti-inflammatory mechanisms 
in combination with a resulting or parallel antifibrotic 
effect. Pioglitazone counteracts in vitro, where insulin 
sensitization does not operate, the podocycle cell cycle 
arrest and apoptosis, with the consequent podocyte loss 
and hypertrophy, induced by hyperglycemia  [25] . The ef-
fects of pioglitazone and PPAR-  agonists through glyce-
mic control and local mechanisms on other landmarks of 
diabetes nephropathy, such as abnormal angiogenesis, 
endothelial dysfunction, or even key markers of renal fi-
brosis, are less clear.
 In the current work we aimed to expand our previous 
findings by confirming with additional markers the pro-
tective effects of low doses of pioglitazone on renal fibro-
sis and inflammation in the ZDF, and associating them 
with new mechanistic insights based on the modulation 
by the drug of tubular pathology, cell replication, apo-
ptosis, angiogenesis, and the eNOS/iNOS balance.
 Methods 
 Animals and Treatments 
 All the experiments were approved by the Institutional Ani-
mal Care and Use Committee (IACUC) of Hospital Alemán, Bue-
nos Aires, Argentina, and of LABioMed at Harbor-UCLA, Tor-
rance, Calif., USA, and according to the NIH Guide for the Care 
and Use of Laboratory Animals. Twelve-week-old male Zucker 
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diabetic fatty rats (ZDF) and control lean (LZR) (Charles River 
Laboratories, Wilmington, Mass., USA) were housed in individ-
ual cages at 21  8 2  °  C and a 12-hour light/darkness cycle (7 a.m.–
7 p.m.), and divided into three groups (n = 8/group), similar to 
some experimental groups used previously  [22] : G1: ZDF, fed reg-
ular Purina 5008 chow; G2: ZDF, fed with chow containing 
0.001% (‘low-dose’) pioglitazone, calculated from the daily food 
eaten as an approximate dose of 0.6 mg/kg/day, and G3: LZR, fed 
regular chow. Blood for biochemical determinations was with-
drawn at baseline and then monthly throughout the experiment. 
After 4 months of treatment all rats were euthanized by subtotal 
exsanguination under anesthesia (sodium thiopental, i.p.). The 
kidneys were rapidly excised, weighed and harvested, fixing the 
left kidneys in 10% neutral buffered formalin, followed by embed-
ding in paraffin for histochemical and quantitative immunohis-
tochemical studies. The right kidneys were preserved by immers-
ing in liquid nitrogen and storing at –80  °  C.
 Blood Pressure and Biochemical Determinations 
 At baseline and then monthly, systolic blood pressure and dia-
stolic blood pressure were measured by a non-invasive pressure 
device using volume pressure recording, CODA 2 (Kent Scien-
tific Co., Torrington, Conn., USA). Measurements were obtained 
in non-anesthetized rats restrained in a thermic plastic cham-
ber  [22] .
 After 14-hour fasting, rat blood samples were collected and   -
smooth muscle actin and sera were obtained from duplicate spec-
imens and frozen at –20  °  C.   -Smooth muscle actin glucose levels 
were measured by the glucose oxidase method with an Automat-
ic Analyzer (Hitachi 911, Tokyo, Japan). Serum cholesterol and 
triglycerides were assessed according to standard methods. Se-
rum insulin was determined by sensitive rat insulin RIA kit (SRI-
13; Linco Research, St. Charles, Mo., USA). Serum electrolytes 
were determined by standard methods.
 Immunohistochemical and Immunofluorescence Procedures 
 For immunohistochemical determinations,  paraffin-embed-
ded 3-  m tissue sections were deparaffinized and dehydrated. 
Endogenous peroxide activity was blocked by treating with 0.5% 
H 2 O 2 in methanol for 30 min. Immunohistochemical assays 
were conducted essentially as previously reported  [22] . The fol-
lowing antibodies were used: (1) goat anti-rat TNF-  AF-510-
NA, 1: 50 (R&D Systems, Inc., Minneapolis, Minn., USA); (2) 
mouse anti-human VEGF (sc7269), 1: 150; (3) goat anti-mouse 
IL-6 (sc1265), 1: 100; (4) goat anti-human fibronectin (sc6952),
1: 100; (5) goat anti-human CTGF (sc14939), 1: 50; (6) rabbit poly-
clonal IgG anti-MCP-1 (ab-7202; Abcam, Cambridge, UK),
1: 100; (7) rabbit anti-human eNOS or NOS3 (sc654), 1: 150; (8) 
rabbit anti-human iNOS or NOS2 (sc651), 1: 150; (9) mouse anti-
rat PCNA (sc56), 1: 100 (2–8 from Santa Cruz Biotechnology, 
Inc., Santa Cruz, Calif., USA); (10) rabbit anti-human caspase-3 
AB-3623, 1: 50 (Chemicon International, Inc., Temecula, Calif., 
USA), and (11) mouse anti-rat ED1 MAB1435, 1: 100 (Chemicon 
International, Inc.).
 Immunostaining was carried out with a commercial modified 
avidin-biotin-peroxidase complex technique, Vectastain ABC kit 
(Universal Elite, Vector Laboratories, Calif., USA), and counter-
staining with hematoxylin. For immunofluorescence observa-
tions, frozen sections (5   m) were treated with a goat polyclonal 
IgG anti-megalin (P-20) (1: 50, sc16478; Santa Cruz Biotechnolo-
gy, Inc.) followed by donkey anti-goat IgG-FITC (1/100) (sc2024; 
Santa Cruz Biotechnology, Inc.).
 In all cases, negative controls consisted of histological sections 
incubated with PBS rather than the primary antibody. Immuno-
staining was visualized on a Nikon E400 fluorescence microscope 
equipped with a high-pressure mercury lamp. Images were ac-
quired with a digital camera and processed (Nikon Instrument 
Group, Melville, N.Y., USA).
 Quantitative Image and Morphological Analysis 
 Five  stained histological sections were studied for each kidney. 
All tissue samples were evaluated independently by two investiga-
tors without prior knowledge of the group to which the rat be-
longed. All measurements were carried out on 20 fields per tissue 
section, using an image analyzer Image-Pro Plus version 4.5 for 
Windows (Media Cybernetics, LP, Silver Spring, Md., USA). Data 
were averaged and the results were expressed as a percentage of 
positive staining/mm 2 and number of cells with positive stain-
ing/mm 2 when appropriated.
 Immunoprecipitation and Immunoblotting 
 Kidney samples were homogenized in 10 volumes of a solubi-
lization buffer containing 1% Triton X-100 Sigma Ultra (Sigma, 
St. Louis, Missouri, Mo., USA), together with protease inhibitors. 
Equal amounts of solubilized proteins (80 mg) were boiled in re-
ducing sample buffer and resolved by SDS-PAGE. Western trans-
fer of proteins to polyvinylidene difluoride membranes was per-
formed. The membranes were then incubated overnight with the 
following antibodies (1: 1,000): anti-CTGF (sc14939), anti-PCNA 
(sc56), anti-caspase-3 (AB-3623), anti-VEGF (sc7269), anti-iNOS 
(sc651), anti-eNOS (sc654). After blocking membranes were incu-
bated for 1 h with goat anti-rabbit IgG horseradish peroxidase 
(HRP) secondary antibody (for caspase-3, iNOS and eNOS) or 
goat anti-goat IgG-HRP (for CTGF) or goat anti-mouse IgG-HRP 
(for PCNA and VEGF). Specific bands were detected by enhanced 
chemiluminescence (Amersham, Piscataway, N.J., USA), and 
their intensities were quantitated by digital densitometry. Each 
marker luminometry determination was performed simultane-
ously for all specimens. Densitometric values for marker bands 
are expressed as arbitrary units for each gel. The intensity of the 
housekeeping   -actin band was used to normalize the marker 
values in each gel.
 Statistical Method 
 Values were expressed as mean  8 SD. All statistical analyses 
were performed using absolute values and processed through 
GraphPad Prism, version 5.0 (GraphPad Software, Inc., San Di-
ego, Calif., USA). The assumption test to determine the gaussian 
distribution was performed by the Kolmogorov-Smirnov meth-
od. For parameters with gaussian distribution, comparisons 
among groups were carried out using one-way analysis of vari-
ance (ANOVA) followed by the Bonferroni’s test, and two-way 
ANOVA for repeated measures was used as appropriate. For those 
parameters like histological data with non-gaussian distribution, 
comparisons were performed by Kruskal-Wallis test (non-para-
metric ANOVA) and Dunn’s multiple comparison test. A value of 
p  ! 0.05 was considered significant.
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 Results 
 Pioglitazone given at the selected low dose to the ZDF 
for 4 months did not virtually reduce blood glucose below 
the 243 mg/dl previously established as threshold in both 
the ZDF and the OZR  [22] , as evidenced by the time 
course (not shown) represented by the basal and final val-
ues ( table 1 ). The latter were still nearly 2.5-fold higher 
than in the LZR and similar to the hyperglycemia that in 
the OZR remained unchanged in the low-dose pio-
glitazone treatment  [22] . As expected, body weight was 
not affected in the moderately obese ZDF. Although tri-
glycerides and cholesterol were reduced as compared to 
basal values and those in the untreated ZDF, they were 
still considerably elevated in comparison to the LZR. Se-
rum insulin remained unchanged and at the low levels 
that characterize the progressive hypoinsulinemia found 
in this strain. Taken together, this confirms the premise 
that pioglitazone at this low dose, despite reducing glyce-
mia, does not exert an effective metabolic syndrome con-
trol. However, this treatment considerably ameliorates 
proteinuria, systolic and diastolic blood pressure, and to 
a lesser extent creatinine clearance, during the time 
course (not shown) represented by the basal and final 
data in  table 1 . Also, as expected, serum levels of sodium 
and potassium were not affected either by diabetes or by 
treatment with pioglitazone (not shown).
 The reduction in renal tubulointerstitial fibrosis by this 
regimen that we previously reported  [22] was now con-
firmed, since the percentage of tubulointestitial fibrosis 
(mean  8 SD) was 16.0  8 3.1 for ZDF, 6.1  8 1.7 * for ZDF 
+ pioglitazone ( * p  ! 0.01 vs. ZDF) and 2.5  8 1.3 + LZR
( + p  ! 0.01 vs. all groups). Similarly, the percentage of glo-
merular sclerosis per glomerulus (mean  8 SD) was now 
26.9  8 5.2 for ZDF, 7.7  8 2.3 * for ZDF + pioglit azone
( * p  ! 0.01 vs. ZDF) and 1.1  8 0.4 + for LZR ( + p  ! 0.01 vs. 
all groups). In this setting, we now found that two addi-
tional markers, connective tissue growth factor (CTGF) 
( fig.  1 a–d) and fibronectin ( fig.  2 a), were considerably 
overexpressed in the ZDF as compared to the LZR. This is 
seen in the representative micrographs for CTGF (the ones 
for fibronectin are not shown because of space limitations) 
and the quantitative estimations by image analysis for 
both proteins. CTGF showed granular cytoplasm distribu-
Table 1.  Body weight, blood pressure and laboratory parameters
a Baseline
ZDF (n = 8) ZDF + PGT (n = 8) LZR (n = 8)
Body weight, g 397.1820.0 400.7818.2 265.9815.9*
Systolic blood pressure, mm Hg 122.582.8 122.883.5 120.283.3
Diastolic blood pressure, mm Hg 75.482.1 74.982.2 73.581.9
Glycemia, mg/dl 395.6840.6 404.5835.1 96.0814.4*
Serum insulin, ng/ml 38.685.9 37.385.2 5.180.9*
Triglycerides, mg/l 598.8845.9 601.3855.7 35.989.7*
Cholesterol, mg/l 145.7820.1 153.3818.7 55.684.8*
Creatinine clearance, ml/min 3.280.4 3.180.5 3.080.3
Proteinuria, mg/day 18.385.0 20.384.2 2.380.1*
b At the end of the experiment (4 months)
Body weight, g 502.6814.3 484.2816.4 396.9820.2*
Systolic blood pressure, mm Hg 160.585.1 134.184.2** 123.883.7*
Diastolic blood pressure, mm Hg 96.082.8 81.882.3** 74.182.2*
Glycemia, mg/dl 475.6850.2 243.3830.7** 115.8810.5*
Serum insulin, ng/ml 8.883.1 10.182.8 3.481.2*
Triglycerides, mg/l 587.3859.4 223.6821.6** 39.588.4*
Cholesterol, mg/l 176.5823.1 95.2810.6** 57.284.6*
Creatinine clearance, ml/min 2.280.2* 2.980.3 3.080.2
Proteinuria, mg/day 234.1830.2 56.389.1** 7.382.5*
Values are mean 8 SD. * p < 0.01 vs. all groups. ** p < 0.01 vs. ZDF. PGT = Pioglitazone.
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tion in distal tubular epithelial cells and cortical collecting 
tubules. Treatment with pioglitazone normalized the ex-
pression of CTGF, as confirmed by quantitative Western 
blot for the 38-kDa band ( fig. 1 e), and also considerably 
diminished fibronectin levels ( fig. 2 a).
 In turn, the anti-inflammatory effect of the drug that 
may mediate the antifibrotic response, also shown previ-
ously  [22] , was confirmed by the considerable decrease in 
interleukin-6 not only in the glomerular area but also in 
epithelial tubular cells in the treated ZDF (IL-6) ( fig. 2 b) 
and the normalization of two other indicators, tumor ne-
crosis factor-  (TNF-  ) and monocyte chemotactic pro-
tein (MCP-1) ( fig.  2 c, d, respectively). For the sake of 
space the representative micrographs are omitted, and 
only the bar graphs are shown. The positive immuno-
staining was detected for fibronectin in the cortex in the 
interstitium and in distal tubular epithelial cells, for IL-6 
in mesangial cells as well as in distal tubular epithelial 
cells, and for MCP1 in proximal and distal tubular epi-
thelial cells and in mesangial cells. The ED1 determina-
tion previously reported for the corresponding rat groups 
was repeated in this new series and gave essentially simi-
lar results, where the number of positive cells per area 
(mean  8 SD) was 17.4  8 4.1 for ZDF, 3.4  8 1.0 * for ZDF 
+ pioglitazone ( * p  ! 0.01 vs. ZDF) and 1.3  8 0.8 + for LZR 
( + p  ! 0.01 vs. all groups). Positive ED1 cell peritubular 
infiltration was detected mainly in the cortex.
 Having confirmed in these groups of rats the improve-
ment of kidney function and expanded the characteriza-
tion of the anti-inflammatory and antifibrotic effects of 
pioglitazone at a dose that exerts a very poor glycemic 
control, we then examined the impact of diabetes and the 
drug on processes affecting the cellular content mainly in 
the glomeruli but also in the extraglomerular area. Mega-
lin expression detected by immunofluorescence showed 
a linear/pseudolinear positive fluorescence pattern in 
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 Fig. 1. A low dose of pioglitazone (PGT) normalized the expres-
sion of the fibrosis marker, connective tissue growth factor 
(CTGF), in renal tissue in type 2 diabetic rats.  a–c Representative 
micrographs of renal tissue subjected to immunostaining.  ! 400. 
Arrows indicate overexpression of CTGF.  a ZDF (Zucker diabetic 
fatty);  b ZDF treated with PGT;  c LZR (lean Zucker rats).  d Bar 
graph representing the percentage of positive staining in all 
groups.  e Western blot bands and densitometry. 
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apical position of proximal tubular epithelial cells ( fig. 3 ). 
This has revealed now that a tubular marker (not previ-
ously investigated) was restored by this treatment to the 
levels seen in the LZR, despite the still considerable hy-
perglycemia.
 The cellular protective impact of this treatment was 
confirmed by the determination of the proliferation and 
apoptotic indexes, evaluated separately by the number 
cells positive for proliferating cell nuclear antigen (PCNA) 
( fig. 4 a, b) and for caspase-3 ( fig. 4 c, d), respectively. The 
positive staining for both markers was evident in proxi-
mal tubular epithelial cells as well as in podocytes ( fig. 4 a, 
c). Type 2 diabetes in the ZDF induced a considerable and 
unexpected increase of the proliferation index that was 
normalized by pioglitazone to the values found in the 
LZR. Remarkably similar changes were found for the 
apoptotic index. This was confirmed by quantitative 
Western blot for the 34- and 17-kDa bands for PCNA and 
caspase-3, respectively ( fig.  4 b, d). When the ratio be-
tween both indexes was established, then the cellular 
turnover did not show significant differences between 
the ZDF (1.01  8 0.09) and the LZR (0.81  8 0.29), but 
pioglitazone increased this ratio (1.35  8 0.30) moder-
ately but significantly (p  ! 0.01), suggesting that the drug 
enhanced cell replication over cell death.
 The beneficial effects of pioglitazone were reaffirmed 
by the fact that a proapoptotic agent, iNOS, that in addi-
tion has pleiotropic effects on cell turnover, angiogenesis 
and fibrosis, was considerably upregulated in the ZDF 
kidney, but pioglitazone abrogated this expression to the 
negligible levels seen in the LZR ( fig. 5 a–d). The immu-
nostaining was seen in the brush border of proximal tu-
bular epithelial cells. Furthermore, cortical collecting tu-
bules and podocytes showed granular cytoplasm distri-
bution. The Western blot quantitative assay ( fig. 5 e) was 
in good agreement for the 130-kDa band.
 Since increased VEGF expression is known to be a 
main factor in the abnormal angiogenesis occurring in 
DN, we estimated the effects of pioglitazone and found 
that the low-dose treatment normalized it to the values 
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 Fig. 2. A low dose of pioglitazone (PGT) normalized the expres-
sion of another fibrosis marker, fibronectin, and key inflamma-
tion markers in renal tissue in type 2 diabetic rats. Tissue sections 
were subjected to immunostaining for each of the markers and 
then subjected to quantitative image analysis.  ! 400. The repre-
sentative micrographs for the immunostained tissue sections are 
not included for the sake of space. Bar graphs represent the per-
centage of positive staining for  a fibronectin,  b IL-6,  c TNF-  , and 
 d MCP-1. ZDF = Zucker diabetic fatty; ZDF + PGT = ZDF treated 
with PGT; LZR = lean Zucker rats. 
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found in the LZR ( fig. 6 a–d), and this was accompanied 
as expected by the restoration of the levels of eNOS, a 
marker of endothelial function, that had been consider-
ably downregulated by diabetes ( fig. 7 a–d). The positive 
immunostaining for VEGF was seen with granular cyto-
plasm distribution in distal tubular epithelial cells, corti-
cal collecting tubules and podocytes, and for eNOS in the 
proximal tubular epithelial cells, cortical collecting tu-
bules and podocytes with diffuse cytoplasm distribution. 
The immunohistochemical data was confirmed in both 
cases by quantitative Western blot ( fig. 6 e,  7 e) for the 15- 
and 140-kDa bands for VEGF and eNOS, respectively. 
Interestingly, the ratio between eNOS and iNOS was in-
creased by the drug from 0.21  8 0.08 in the untreated 
ZDF to 6.43  8 3.76 in the treated ZDF (p  ! 0.001), as 
compared to 7.86  8 3.43 in the LZR, as an indicator of a 
positive nitrergic (nitric oxide generator) balance that 
would favor vasodilatory over proapoptotic effects.
 Discussion 
 Our previous work  [22] had demonstrated that pio-
glitazone given at a low dose that did not exert any glyce-
mic control in the OZR, and a very poor one in the ZDF, 
was still able to prevent DN in both strains, by reducing 
blood pressure and combating renal fibrosis, chronic in-
flammation and oxidative stress, as evidenced by the nor-
malization of collagen,   -smooth muscle actin, PAI-1, he-
moxygenase, nephrin, ED1, and other markers. It is im-
portant to stress that in the OZR this dose of pioglitazone 
had virtually prevented the development of DN despite 
that hyperglycemia remained unchanged in this strain, at 
a level similar to the one observed then and now in the 
ZDF (around 250 mg/dl). Here we confirm in the ZDF 
some of these findings with additional markers and ex-
pand the characterization of the drug effects by showing 
that it induces a positive balance of cell turnover and 
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 Fig. 3. A low dose of pioglitazone (PGT) normalized the expres-
sion of a key marker of tubular cells, megalin, in renal tissue in 
type 2 diabetic rats.  a–c Representative micrographs of renal tis-
sue subjected to immunofluorescent detection with IFTC.  ! 400. 
Arrows indicate expression of megalin in the epithelial tubular 
cells.  a ZDF (Zucker diabetic fatty);  b ZDF treated with PGT;
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 Fig. 4.  a–d A low dose of piogli-
tazone (PGT) reduced the compen-
satory overexpression of a prolifer-
ation marker, proliferating cell 
 nuclear antigen (PCNA), and 
 normalized the expression of an 
apoptosis marker, caspase-3, in re-
nal tissue in type 2 diabetic rats. 
Right panels: Representative mi-
crographs of renal tissue subjected 
to immunostaining.  ! 400. Arrows 
indicate expression in both the glo-
merular and epithelial cells, with 
positive nuclear staining. Left pan-
els:  a ,  c Bar graphs representing the 
number of cells with positive im-
munostaining for PCNA and cas-
pase-3 respectively in all groups.
 b ,  d Western blots and densitomet-
ric estimations. ZDF = Zucker dia-
betic fatty rats; ZDF + PGT = ZDF 
treated with PGT; LZR = lean 
Zucker rats. 
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counteracts indicators of tubular pathology, abnormal 
angiogenesis, endothelial damage, and inflammatory ni-
trergic imbalance. The near normalization by low-dose 
pioglitazone of both proteinuria and blood pressure is in 
excellent agreement with the effects observed on all these 
histopathological markers of renal tissue damage. This 
proteinuria control may also contribute to reduce tubu-
lointerstitial inflammation.
 One of the key findings of the current work is the nor-
malization of CTGF and fibronectin levels by this treat-
ment. CTGF is a downstream mediator of TGF-  1 , the 
key profibrotic factor in the diabetic kidney that we had 
shown to be downregulated by low-dose pioglitazone 
 [22] , and that leads to the also previously described exces-
sive collagen I and III production, corrected by pio-
glitazone. CTGF is mainly produced in the podocytes 
 [26] and its   -smooth muscle actin levels are increased in 
diabetic patients and mice, as well as in urine in the mice 
 [27, 28] . Moreover,   -smooth muscle actin CTGF is an 
independent predictor of end-stage renal disease and 
mortality in patients with type 1 diabetes  [29] . Fibronec-
tin is also a well-recognized marker of fibrosis in DN  [30] . 
The fibronectin normalization with our treatment in the 
ZDF is in perfect agreement with CTGF normalization, 
since CTGF induced fibronectin expression in mesangial 
cells concurrent with collagen deposition  [31] . No studies 
are available in vivo on the effects of pioglitazone on both 
markers in DN, although another thiazolidinedione, 
rosiglitazone, did reduce fibronectin expression in a low-
dose streptozotocin-induced diabetes in the mouse, in 
the absence of glycemic control since this is a model of 
mild type 1 diabetes  [32] .
 The prevention of the increase of proinflammatory 
markers by pioglitazone at low doses, previously shown 
just with ED1  [22] and confirmed in the current work, has 
now been more conclusively proven by finding similar ef-
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centage of positive immunostaining in all groups.  e Western blot 
and densitometric estimations. 
 Pioglitazone and Renal Cell Turnover, 
Angiogenesis, and Endothelial Integrity 
Kidney Blood Press Res 2011;34:20–33 29
fects on other key markers of inflammation. They include 
either cytokines, such as TNF-  and IL-6, or a chemo-
taxic factor, MCP-1, which are well known to be associ-
ated with DN  [12, 33] . Pioglitazone at doses exerting gly-
cemic control, and to a lower extent rosiglitazone, low-
ered serum TNF-  in diabetic patients in association 
with reduced albuminuria  [34] , but no changes were ob-
served in another study, even if IL-6 was reduced  [35] . In 
contrast with these conflicting results for TNF-  , rosi-
glitazone does reduce urinary MCP-1 in streptozotocin-
induced diabetic rats  [36] . However, no in vivo studies are 
available for pioglitazone at any dose on IL-6 or MCP-1, 
and in general for any other thiazolidinedione at subop-
timal doses, or again at any dose on the diabetic kidney, 
as opposed to circulating cytokines.
 Along with our innovative results is the normalization 
of the tubular marker megalin by low doses of pio-
glitazone in the kidney of the ZDF, that shows an im-
provement of tubular cell homeostasis in concurrence 
with the previously reported prevention of glomerular 
damage detected by nephrin immunostaining  [22] . 
Megalin is an endocytic receptor on the apical mem-
branes of proximal tubule cells which is involved in the 
reabsorption of proteins filtered by the glomeruli  [37] . 
Very few studies have been conducted so far with this 
marker despite its functional importance, and only one 
report in vivo in the type 1 diabetic kidney showing its 
increase with an anti-TGF-  1 strategy, in association 
with reduced urinary albumin excretion and reduction of 
collagen IV expression, independently from glycemic 
control  [38] . Aberrant shedding of megalin was also 
shown type 1 diabetic patients with microalbuminuria 
 [39] . However, no reports are available on the effect of 
thiazolidinediones on this marker in DN.
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 Fig. 6. A low dose of pioglitazone (PGT) normalized the expres-
sion of an angiogenesis marker, vascular endothelial growth fac-
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 d Bar graph representing the percentage of positive immuno-
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 One of the main features of DN is the loss of both tu-
bular and glomerular cells discussed above, that appears 
to be the target of the recently demonstrated amelioration 
of type 2 DN in OLEFT rats by low-dose pioglitazone, via 
local cell cycle-dependent mechanisms and apoptosis 
(G1-phase cell cycle arrest, and Bcl-2 levels), mainly in 
podocytes, and very importantly without affecting HbA 1c 
levels  [23] . Our results on the increase of the cell replica-
tion/apoptosis balance in glomerular regions, within an 
overall reduced cell turnover, support this concept. We 
are not aware of any other study of thiazolidinediones on 
cell turnover in DN, although the paradoxical reduction 
of PCNA in this work agrees also with prior observations 
on troglitazone in 5/6 nephrectomy  [40] , or on thiazoli-
dinediones effects on apoptosis.
 Our demonstration of renal VEGF reduction has im-
portant implications, since this growth factor overpro-
duction involved in abnormal angiogenesis leads to vas-
culopathy associated with aberrant growth of new blood 
vessels that plays a crucial role in nephropathy  [41] . This 
agrees with the single study we could identify for any thi-
azolidinedione (pioglitazone too in this case), that was 
performed in OLEFT rats but with doses improving in-
sulin sensitivity  [21] . The increase in eNOS observed in 
the current work, somehow paradoxical in terms of the 
VEGF reduction, is however logical by suggesting that 
this treatment increases nitric oxide bioavailability and 
corrects endothelial dysfunction in existing vessels  [12] 
without inducing neoangiogenesis, and possibly being re-
sponsible for the early phase glomerular hyperfiltration 
in DN  [41] . The latter study showed an increase of eNOS 
in the early phase of diabetes in a mouse model, and pio-
glitazone reduced eNOS and corrected glomerular hy-
perfiltration, but the effects on the more advanced stage 
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 Fig. 7. A low dose of pioglitazone (PGT) normalized the expres-
sion of a marker of endothelial integrity and function, endothe-
lial nitric oxide synthase (eNOS), in renal tissue in type 2 diabet-
ic rats.  a–c Representative micrographs of renal tissue subjected 
to immunostaining.  ! 400. Arrows indicate expression not only 
in the glomerular area but also in epithelial tubular cells.  a ZDF 
(Zucker diabetic fatty);  b ZDF treated with PGT;  c LZR (lean 
Zucker rats).  d Bar graph representing the percentage of positive 
immunostaining in all groups.  e Western blot and densitometric 
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were not investigated. We are not aware of any other 
study on renal eNOS levels being affected by thiazoli-
dinediones in DN.
 Finally, our results on renal iNOS reduction in DN are 
also novel in terms of thiazolidinedione effects. They 
would suggest that the antiapoptotic effects of PPAR-  
agonists in the kidney would be in part due to the abroga-
tion of iNOS expression, that by producing sustained ex-
cessive levels of nitric oxide and peroxynitrite would act 
as proapoptotic and stimulator of lipid peroxidation in 
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pears to be involved in the development of type 2 DN in 
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observed abrogation by pioglitazone of iNOS expression 
remains to be determined.
 The studies showing beneficial effects of thiazoli-
dinediones on DN in type 1 animal models  [16, 17] , where 
these drugs do not lower glycemia, prove their direct ac-
tion on the kidney unrelated to glycemic control. Higher 
doses of thiazolidinediones that did exert glycemic con-
trol in patients and rat models but were more effective 
than insulin or metformin in renoprotection also sup-
ported this assumption  [12] . Moreover, pioglitazone has 
been recently shown to protect against non-diabetic 
chronic kidney disease in experimental models where 
glycemic control does not play any role, and specifically 
in renal injury in aging, by reducing proteinuria, improv-
ing GFR, decreasing sclerosis and systemic and renal ox-
idative stress, and improving mitochondrial function, 
through local effects on the kidney  [46] . Antifibrotic and 
protective effects of pioglitazone independent of glyce-
mic control were also shown locally in other tissues, such 
as in the aging penile corpora cavernosa  [47] .
 In the present work, in contrast to the clear-cut lack of 
glycemic control by low-dose pioglitazone in the OZR 
that per se supported our claim of independent local ef-
fects of pioglitazone on the kidney  [22] , there was in the 
ZDFR a significant reduction of glycemia. Even if these 
values did not go below the previously observed threshold 
of 243 mg/dl, we cannot exclude in the ZDFR that part of 
the beneficial effects we have observed in DN are due to 
reducing the severity of the diabetes. However, in the con-
text of the collective evidence on the protective effects of 
pioglitazone and other thiazolidinediones on the kidney 
from models of type 1 diabetes and non-diabetic condi-
tions, and even on other types of fibrosis, and our own 
previous results in the OZR and ZDFR, one may specu-
late that our findings on type 2 DN animal models result, 
at least in part, from a mechanism additional to the wide-
ly accepted systemic glycemic control  [12] . Similarly, al-
though a systemic effect on the lowering of blood pres-
sure observed here cannot be denied, the improvement of 
the nephropathy by alternative local mechanisms would 
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 Our assumption that still requires direct proof is that 
the binding of ligands such as thiazolidinediones to 
PPARs in the kidney glomerular, tubular, mesangial, and 
endothelial cells  [48–50] would contribute in DN to trig-
gering not just the previously demonstrated anti-inflam-
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trergic balance (eNOS/iNOS), thus confirming many 
predictions from vascular studies.
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